StaupriMide manufacturers and suppliers

StaupriMide suppliers

StaupriMide

CAS:: 154589-96-5

MF:: C35H28N4O5

MW:: 584.62

Suppliers by country/region

Company Type

Properties

Density: 1.52±0.1 g/cm3(Predicted)

storage temp.: -20°C

solubility: DMSO: >20mg/mL

pka: 9.51±0.70(Predicted)

form: Yellow solid

color: white to beige

Stability:: Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.

Safety Information

Symbol(GHS): GHS07

Signal word: Warning

Hazard statements: H315-H319-H335

Precautionary statements: P261-P271-P280

WGK Germany: 3

HS Code: 2934999090

Use

Stauprimide is an enhancer stem cell differentiation into endoderm. In vitro differentiation of embryonic stem cells is of great interest to regenerative medicine, and current protocols are labor-intensive and expensive. Small molecules that induce or enhance differentiation are highly desired. High-content screening identified compounds that enhance endodermal differentiation in the presence of low levels of Activin A. Stauprimide increased definitive endodermal markers but not markers for visceral/parietal endoderm or mesoderm. Stauprimide-differentiated cells could be further differentiated into hepatocytes. Stauprimide treatment during differentiation decreased the concentration of Activin A required for definitive endoderm formation, and it eliminated the need for serum. The mechanism of action of stauprimide is to sensitize cells for differentiation. Stauprimide enabled differentiation into other cell lineages under varying differentiation conditions, including neurons, hematopoietic mesoderm, beating cardiac myocytes, and skeletal muscle. Stauprimide is a semi-synthetic analogue of the staurosporine family of indolocarbazoles. Stauprimide was first published in 1994 as part of an extensive structure-activity investigation to improve the selective inhibition of protein kinase C as potential antitumour agents. Stauprimide increases the efficiency of the directed differentiation of mouse and human embryonic stem cells in synergy with defined extracellular signalling cues. Stauprimide interacts with NME2 (PUF) transcription factor to down-regulate c-Myc expression, leading to differentiation of stem cells. Labelled Stauprimide (S684700). It is an enhancer stem cell differentiation into endoderm. Stauprimide is a semi-synthetic analogue of the staurosporine family of indolocarbazoles. Stauprimide was first published in 1994 as part of an extensive structure-activity investigation to improve the selective inhibition of protein kinase C as potential antitumor agents. Stauprimide increases the efficiency of the directed differentiation of mouse and human embryonic stem cells in synergy with defined extracellular signalling cues. Stauprimide interacts with NME2 (PUF) transcription factor to down-regulate c-Myc expression, leading to differentiation of stem cells.

You can find StaupriMide suppliers, manufacturers, and distributors from countries such as CHINA, United States and the United Kingdom here. Browse to the tetrahydrofuran product information displayed by the supplier, as well as the supplier's contact and capability information.